✦ LIBER ✦

Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer

✍ Scribed by C. Bokemeyer; H. -J. Schmoll; F. Natt; M. Knoche; J. Beyer; R. Souchon

Book ID: 112496253
Publisher: Springer-Verlag
Year: 1994
Tongue: English
Weight: 387 KB
Volume: 120
Category: Article
ISSN: 1432-1335
DOI: 10.1007/bf01194278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Irinotecan in patients with relapsed or

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

✍ Kollmannsberger, C; Rick, O; Klaproth, H; Kubin, T; Sayer, H G; Hentrich, M; Wel 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 76 KB

A phase II trial of a paclitaxel and oxa

A phase II trial of a paclitaxel and oxaliplatin combination in advanced ovarian cancer patients pretreated with cisplatin or carboplatin ± taxanes: Preliminary results

✍ Viens, P.; Bougnoux, P.; Rixe, O.; Petit, T.; Laadem, A.; Cottu, P.; Delva, R.; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 186 KB

Reply: Irinotecan in patients with relap

Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

✍ Kollmannsberger, C; Bokemeyer, C 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 55 KB

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Preliminary results from a Phase II tria

Preliminary results from a Phase II trial of EPO906 in patients with advanced refractory ovarian cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Prolonged administration of oral etoposi

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial

📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 173 KB